Wednesday 31 July 2013

Therapeutic vaccines function by triggering a body immune response against a disease. The global therapeutic vaccines market was valued at USD 292 million in 2011. The introduction of therapeutic vaccines has opened up new avenues in the field of chronic disease treatment and prophylactic immunization. Provenge was the first U.S. FDA approved immunotherapy drug to treat prostate cancer in men in 2010, which has encouraged rigorous research and development initiatives by pharmaceutical companies to develop novel vaccines for untapped disease segments. As a result of these initiatives, many more therapeutic vaccines are currently in the pipeline such as breast cancer vaccine, lung cancer vaccine; Alzheimer’s vaccine, malaria vaccine, and diabetes vaccine are expected to be introduced in the market during the period from 2012 to 2018.

Browse for full report: Therapeutic Vaccines Market 

The market is currently facing growth hindrances as R&D approaches, and regulatory and reimbursement policies are inconspicuous owing to the nascent nature of the market. However, regulatory bodies are working enthusiastically to lay out policies and growth strategies, due to the fact that it holds the potential to solve or curb chronic diseases, with no currently available treatments, such as HIV AIDS.

Four components hold imperative importance in designing a therapeutic vaccine:
  • Antigens: These are substances that evoke an immune response from the body and are responsible for the production of antibodies
  • Adjuvants: These are immunological agents that help in modifying the effects of a drug or vaccine. Companies are now engaged in designing new adjuvants that will help in enhancing the immunogenicity of an antigen
  • Cost effective production systems for vaccines
  • Designing innovative drug delivery devices to enhance vaccine efficacy 
The North American therapeutic vaccine market is expected to generate the maximum revenue in the global market during the forecasted period due to the presence of efficient R&D facilities and sophisticated medical infrastructures. The market is segmented into three major application segments namely oncology, infectious diseases and other chronic disorders. The therapeutic vaccine market with oncology applications market held the majority of the market share in 2011, as most of the research and development exercises are expected to be directed towards this segment during 2012 to 2018.

Merck and GSK have strong therapeutic vaccine product pipelines and are expected to perform better during 2012 to 2018 than their competitors who have fewer products in the pipeline. Some of the other key players of the market include Sanofi-Pasteur, Cytos Biotechnology AG, and Intellect Neurosciences.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.
Hepatitis is a medical condition characterized by inflammation of the liver which often leads to other complications such as jaundice, anorexia, liver failure and cirrhosis. Hepatitis is generally of two types- acute when it lasts for less than six months and chronic when it lasts for longer period. It can be caused by a group of viruses called as hepatitis viruses which include groups A, B, C, D, and E. The most observed types of this disease are hepatitis A, hepatitis B and hepatitis C. Globally, 350 million people are chronically infected with any one form of hepatitis and around 500,000 people die every year according to World Health Organization.

Browse for full report: Hepatitis Diagnostic Market

Hepatitis A is a simpler form of which does not lead to chronic infections. Patients suffering from hepatitis A recover within two months as this form is less complicated and can be prevented with vaccination. Although hepatitis B can be prevented by vaccination, once infected, a person can develop lifelong chronic infection resulting into severe liver damage. More than 2 billion people of the global population are infected with hepatitis B. Hepatitis C is most dangerous of among all the types of hepatitis as 80% of the hepatitis C infected patients get chronically infected. Around 150 million people are infected with hepatitis C worldwide and 350,000 people die every year. No vaccine is yet available for prevention of hepatitis C.

Hepatitis A, B, C, D and E can be diagnosed by combinations of various specific tests containing enzymes, antibodies and antigens. These are: enzyme immunoassay (EIA), recombinant immunoblot assay (RIBA), transcription-mediated amplification (TMA) and polymerase chain reaction (PCR). The EIA technology is used for antibody as well as antigen detection whereas the other technologies are used to test DNA and RNA to check the presence of hepatitis viruses.

Hepatitis A and E are mainly caused by consumption of contaminated food or water. Hepatitis B, C and D occur as a result of contact with infected body fluids. Common modes of transmission and infection for these viruses include receipt of infected blood or blood products, invasive medical procedures using contaminated equipments. Hepatitis B can be transmitted from mother to baby at the time of birth and by sexual contact. Prevalence of hepatitis A, hepatitis B and hepatitis C in North American countries is 33%, 5% and 1.5% respectively. Thus, North America has registered the highest cases of hepatitis infections followed by Asia-Pacific and then Europe.

Some of the key players involved in the development of diagnostics for hepatitis are Siemens AG, MedMira Inc., Inovio Pharmaceuticals, Inc. and Abbott Laboratories.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Tuesday 30 July 2013

Lymphoma is a kind of blood cancer which occurs when B or T lymphocytes and leukocytes grow abnormally. In addition, it also occurs if these cells survive longer than their normal life cycle. Lymphoma generally occurs in lymph nodes, bone marrow, spleen, blood and other organs which form a part of the lymphatic system. The common symptoms of lymphoma are swelling of lymph nodes, fever, weight loss, night sweets, anorexia, itching, dyspnoea and fatigue. The common tests applied for the diagnosis of lymphoma are immunophenotyping, FISH (Fluorescence in Situ Hybridization) testing and flow cytometry. The most common method to threat lymphoma is chemotherapy.

Browse for full report: Lymphoma Treatment Drugs Market

Since chemotherapy destroys the cancer cell by obstructing its division process, it acts as one of the key method for lymphoma treatment. These medicines travels throughout the body while medication. Various drugs are used for the treatment of lymphoma such as Adcertis (brentuximab), Arranon (nelarabine), Adriamycin (doxorubicin), Decadron (dexamethasone), Baycadron (dexamethasone), Deltasone (prednisone), Dexamethasone Intensol (dexamethasone), Dexpak Taperpak (dexamethasone) and Folotyn (pralatrexate). Other drugs used include Prednicot (prednisone), Roferon-A (interferon alfa-2a), Solurex (dexamethasone), Leukeran (chlorambucil), Zema Pak (dexamethasone), Velcade (bortezomib), Sterapred DS (prednisone), Thioplex (thiotepa), Velban (vinblastine) and Trexall (methotrexate).

Rise in the incidence of lymphoma throughout the globe would boost the growth of lymphoma treatment drugs market. According to Leukemia and Lymphoma Society, in 2012, around 700,000 people were suffering from lymphoma in Canada alone. The government of various nations such as U.S. and Europe has amplified their funding for R&D on lymphoma treating drugs which would further augment the growth of this market. Moreover, they have started many programs for patient awareness about lymphoma and its treatments. Despite all these advantages, various side effects of chemotherapy would hamper the growth of this market. These side effects include hair loss, nausea, vomiting and fatigue. In addition, high cost of this treatment would also hamper the growth of this market. Moreover, few nations such as U.K are not providing reimbursement for every lymphoma treating drug which would hamper its growth in this region. Some of the major players in lymphoma treatment drugs market includes Abbott Laboratories, Eli Lilly, Bristol-Myers Squibb, Abiogen, Johnson & Johnson, Aeterna Zentaris among others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.
Anti-infective agents are drugs used for the purpose of killing and/or suppressing the infection causing organisms from invading the host organism by means of its replication or releasing variety of toxins in the host. Such infection causing micro-organisms include viruses, bacteria, fungi, viroids and macro parasites. Infections thus caused can be classified depending on the type of organism causing infection and the symptoms and medical signs shown by host. 

Browse full report at: Anti-Infectives Market

The global market for anti-infectives is classified by product type as antifungal, antiviral and antibacterial depending on the type of organism they fight. Geographically, North America is the most dominating region in the anti-infectives market and is followed by Europe. The emerging economies of Asia-Pacific regions are also showing growth potential in the global anti-infectives market. India forecasts high potential for growth in demand for anti-infectives due to existence of large patient pool, the government initiatives of undertaking various control programs and private partnership projects and rising cost containment initiatives by drug manufacturers.

Some of the major driving factors for the anti-infectives market include increase in patient population, large number of vaccines gaining approvals and newer drug introductions. The growing resistance of infection causing organisms to the existing drug therapies could pose a major challenge to the anti-infectives market. Furthermore, high price of drugs, dicey reimbursement policies and competition between generic manufacturers may hold back the growth of this market. The anti-infectives market is highly fragmented with a large number of domestic and international players. Developmental focus of anti-infective agents has shifted to antiviral agents due to requirement of longer treatment regimens in large number of patient population with chronic indications as compared to antifungal and antibacterial agents requiring shorter treatments.

Some of the key players contributing to the growth of this market include Abbott Laboratories Limited, Cipla Ltd., Claris Life Sciences Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Panacea Biotech Ltd., Pfizer Ltd., Ranbaxy Laboratories Ltd. and Sun Pharmaceutical Industries Ltd.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
All new upcoming reports: http://www.transparencymarketresearch.com/latest.php?type=U

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Monday 29 July 2013

Aptamers refer to short strands of nucleic acids or peptide molecules capable of forming secondary and tertiary structures. These molecules bind specifically to the cellular targets and are created by selecting randomly from the complex libraries of synthetic nucleic acids. These receptor molecules can be modified in order to enhance the stability and availability in biological environments. Aptamers possess potential applications in research, clinical, industrial and medical areas. Since the 1990s, aptamers have been tested for their clinical relevance. Aptamers are chemically equivalent to protein therapeutics and are highly specific, non-immunogenic and small in size. Despite of its advantages over protein therapeutics, aptamers are not able to establish their strong presence in the market. According to a research study published in 2010, till date only one aptamer based drug has received regulatory approval. The first aptamer based therapeutic was indicated for the treatment of age related macular degeneration and was FDA approved in the year 2004. At present many other aptamer molecules are being evaluated in clinical trials.


Emergence of aptamer molecules in various diagnostic and therapeutic applications holds immense growth prospects in the near future. With the development of systematic evolution of ligands by exponential enrichment (SELEX) process, aptamers are replacing antibodies in both diagnostic and therapeutic applications. Aptamers market can be categorized on the basis of product type, applications and geographies. The application areas of aptamers include diagnostics, biosensors, drug discovery, bio-markers, therapeutics and others. The major product types of aptamers include nucleic acid and peptide aptamers. High specificity, intensive research initiatives, wide application areas, technological advancement and heavy investments by manufacturers are some of the factors driving the growth of the global aptamers market. Less accessibility, low awareness, stringent governmental regulations and difficult commercialization of aptamer products are the major challenges prevalent in this market. Technological advances in the fields of targeted therapies, nanotechnology and medical imaging facilitate sustainable growth opportunities for aptamers market. In addition, rigorous research in pipeline creates the possibility of replacement of antibody therapies in the near future.

Aptamer Solutions, Ltd, Aptares AG, AM Biotechnologies LLC, OTC Biotech, Pfizer, Inc., Base Pair Biotechnologies, Trilink Biotechnologies, Inc. and Aptamer Sciences, Inc. are some of the leading players in the global aptamers market.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Thursday 25 July 2013

Autacoids are certain biological factors that act like hormones and help in treating local injuries and other ailments. Autacoids are temporarily formed in the body and act locally. They have many different actions such as modulation of action of glands, smooth muscles, platelets, nerves, and other tissues. They are released by stimuli and when they are released into the body, they can bring certain changes such as itching, skin reddening, and bronchospasms. Some of these changes are undesirable and for the prevention of such symptoms, autacoids antagonists are used.


Autacoids are classified into decarboxylated amino acids, polypeptides, and eicosanoids. The major forms of decarboxylated amino acids are histamine and serotonin. The major polypeptides in autacoids are angiotensin, vasopressin, plasma kinin, substance P, vasoactive intestinal polypeptide, and slow reacting substances of anaphylaxis. It has been recently discovered that some autacoids such as histamine, serotonin, and prostaglandin are found in nerve tissues. The major functional applications of autacoids are in treating inflammation, allergies, neurotransmission, anaphylactic reactions, gastric acid secretion, and neuroendocrine regulation.

It is estimated that the global market for autacoids and related drugs will cross the 100 billion mark by 2018. The major drugs related to autacoids are biogenic amines, polypeptide autacoids, drugs related to lipid-derived autacoids, and drugs related to endothelium derived autacoids. The dominant segment in the autacoids market is biogenic amines. This segment captures more than 65% of the overall autacoids market. The major application segment of the  market are the use of autacoids related drugs in respiratory and cardiovascular diseases, CNS diseases, antiemetics, gastrointestinal diseases, eye disorders, and analgesics.

Some of the major market players in the autacoids and autacoids related drugs market are Abbott Laboratories, APP Pharma, AstraZeneca, Bedford Laboratories, Bristol-Myers Squibb, Chattem Inc., Hospira Inc., Sanofi-Aventis, Xanodyne, and some others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments.

Wednesday 24 July 2013

Market Research Reports : Transparency Market Research published new market report "Pain Management Devices Market (Electrical Stimulators, Radiofrequency Ablation, Analgesic Pumps, Neurostimulation Devices) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018", in 2011, the global pain management devices market was valued at USD 2.0 billion and is expected to grow at a CAGR of 13.1% from 2012 to 2018 to reach a market of USD 5.0 billion by 2018.


Increased sophistication and technological advances have revolutionized the pain management sector. Significant research to understand various pain sensations and their neurotransmission processes has helped in pain reduction to a great extent. A rise in aging population has consequently led to a rise in chronic diseases such as arthritis, diabetes and cancer. In addition, serious side-effects caused due to prolonged use of pain management drugs have triggered the growth of the pain management devices market.Pain management devices comprise a variety of instruments such as electrical stimulators, analgesic pumps, radiofrequency ablation and neurostimulation devices.

Robust support from healthcare institutes, universities and hospitals coupled with positive involvement from government bodies has unquestionably assisted in further growth of this sector. Companies in this sector are collaboratively working towards the introduction of innovative products which would satisfy the unmet needs of patients. Moreover, limitations like miniaturization, achievement of read out time and cost efficiency are being worked on by all the major players of this market.

Electrical stimulators especially the TENS (Transcutaneous Electrical Nerve Stimulators) are currently the most widely used by patients. The market for electrical stimulators was valued to be USD 208.7 million in year 2011 and is expected to grow at a CAGR of 8.2% from year 2012 to 2018. Although electrical stimulators and analgesic pumps are currently the most commonly used devices, radiofrequency ablation (RF ablation) and neurostimulation devices are anticipated to register high growth rate in the coming years of forecast. The rise in neuropathic diseases such as trigeminal neuralgia, peripheral neuralgia and spinal injuries has encouraged the growth of the neurostimulation devices market, which is slated to grow at a CAGR of 15.2% from 2012 to 2018.

Geographically, the North American region constituted the largest market in the year 2011; however, Asia is predicted to foresee the highest growth rate of 21.7% from 2012 to 2018. 
This growth has been attributed to increase in disease awareness and rising disposable incomes. In addition, the Asian region has been predicted to have the highest incidence rates of cancer and diabetes by 2020, by the World Health Organization. Favorable reimbursement policies and research funding by governments in the region will also provide the required impetus for the growth of the market.

The pain management devices market is predominantly an oligopolistic market and is ruled by players such as Medtronic Inc, St. Jude Medical, Boston Scientific, Kimberly Clark and others.

The global pain management devices market has been segmented as below:

Pain Management Market, By Types
  • Electrical Stimulators
    • TENS
    • Others
  • Analgesic Pumps
    • Intrathecal pumps
    • External pumps
  • Radiofrequency Ablation Devices
  • Neurostimulators
    • Spinal Cord Stimulators (SPS)
    • Sacral Nerve Stimulators (SNS)
    • Deep Brain Stimulators (DBS)
Pain Management Market, By Applications
  • Cancer Pain
  • Neuropathic Pain
  • Facial & Migraine Pain
  • Musculoskeletal Pain
  • Trauma
Pain Management Market, By Geography
  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)





Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453



Market Research Reports : Transparency Market Research published new market report "Aerospace Plastics Market for Fuselage, Wings and Empennage Applications in Commercial Aircrafts, Military Aircrafts, Rotary Aircrafts and General Aviation - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018", the global aerospace plastics market was worth USD 6.2 billion in 2011 and is expected to reach USD 10.5 billion in 2018, growing at a CAGR of 7.9% from 2012 to 2018. In terms of volume, the aerospace plastic consumption was 40.5 kilo tons in 2011 and is expected to reach 87.8 kilo tons in 2018, growing at a CAGR of 11.7% from 2012 to 2018.


Steady growth in the aviation industry, excellent strength to weight ratio, and increased adoption of aerospace plastics in aircraft designs are largely augmenting the growth of the aerospace plastics market. EPA (Environmental Protection Agency) and Greenpeace regulations that are imposed upon the production of aerospace plastics are acting as a challenge for the growth of this market. These conventions primarily monitor the percentage of greenhouse gases emitted during the production of aerospace plastics. Furthermore, the high cost of raw materials, namely PAN (Polyacrylonitrile), utilized in manufacturing the aerospace plastics are acting as a restraint for this market.

This study is a comprehensive estimation and analysis of four key end-user segments. The commercial aircrafts end-user segment accounted for 72% of market share in 2011 followed by military aircrafts, rotary aircrafts, and general aviation planes end-user segments. Aerospace plastics market is categorized into six application segments. Fuselage was the key application segment that accounted for over 28% of market share in 2011. Wings, empennage, flight deck and cabin areas are a few other key application segments estimated and analyzed in this study.

In terms of volume, Europe dominated the global aerospace plastics market that accounted for more than 43.0% of the overall market in 2011. In Europe, Germany, France, the UK and Spain were the key regional markets and together accounted for more than 75% of the European market. Europe is expected to dominate the aerospace plastics market for the next five years, owing to the supportive government policies and rising investments seen in Europe over the past three years. Some of the European public bodies such as ONERA, CNES, and CNRT are inventing new materials that are in turn attracting aircraft manufacturers in this region.

The U.S. aerospace plastics market had grown at a steady rate even during economic slowdown, primarily due to reasonable demand in the airlines industry. Increased air traffic and substantial rise in the military budget have provided adequate growth impetus for the North American aerospace plastics market. Asia Pacific is expected to drive the aerospace plastics market chiefly due to low labor overheads and huge investments. In Asia Pacific, the military aircrafts end-user segment is expected to grow, owing to adequate financial support provided by the government.

Some of the key players supplying aerospace plastics include Hexcel Corporation, Mitsubishi Rayon, SGL Carbon, Toho Tenax, Toray Group and Zoltek Companies Inc. The report provides an overview of these companies followed by their financial revenue, business strategies and recent developments.

This research analyzes and estimates the performance and production of aerospace plastics in the global scenario, providing detailed trend analysis of the market by geography and comprehensive analysis of companies that are dealing in aerospace plastics. The report presents a thorough assessment of the strategies followed by different stakeholders by segmenting the aerospace plastics market as below:

  • Aerospace Plastics Market: Application Analysis
    • Airframe and fuselage
    • Wings and rotor blades
    • Empennage
    • Flight deck and cockpit
    • Cabin areas
    • Others (engine and wing box)
  • Aerospace Plastics Market: End-User Analysis
    • Commercial and freighter planes
    • Military aircrafts
    • Rotary aircrafts
    • General aviation
  • Aerospace Plastics Market: Regional Analysis
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Spain
    • Asia Pacific
      • China
      • Japan
      • India
    • Rest of the World (Brazil, Middle East, Africa and Mexico)





Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453


Market Research Reports : Transparency Market Research published new market report “Oral Solid Dosage Forms (OSDF) and Pharma Excipients Market for Polymers (MCC, HPMC, CMC, Ethyl Cellulose, Povidone and Others), Alcohols (Glycerin, Sorbitol, Mannitol, Propylene Glycol), Minerals (Clay, Silicon Dioxide, Titanium Dioxide) and Sugars (Lactose, Sucrose) – Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast, 2012 - 2018,” the global OSDF excipients demand was 93.8 kilo tons in 2011 and is expected to reach 126.8 kilo tons in 2018, growing at a CAGR of 4.5% from 2012 to 2018. In terms of revenue, the market was valued at USD 570.6 million in 2011 and is expected to reach USD 869.1 million in 2018, growing at a CAGR of 6.3% from 2012 to 2018. The overall pharmaceutical excipients demand was 519.5 kilo tons in 2011 and is expected to reach 685.6 kilo tons in 2018, growing at a CAGR of 4.1% from 2012 to 2018.


The growth of the global pharmaceutical market on account of increasing aging population particularly in countries such as U.S. and Japan coupled with the development and introduction of new excipients which exhibit improved properties such as flowability is expected to drive excipients demand over the next five years. However, high costs of manufacturing, stringent government approval process and shortage of approved sites by the Food and Drug Administration (FDA) are expected to hamper the growth of this market.

Polymers were the largest consumed product segment for overall and OSDF excipients market and accounted for over 30% of the global market in both forms. Sugar and other excipient products are expected to witness the fastest growth rate over the forecast period. Within the mineral excipients market, calcium phosphate and calcium carbonate are expected to dominate the market over the next six years. Lactose and sucrose forms of sugar excipients are expected to be the key market segments over the next few years.

Consumption of overall excipients was highest in Europe accounting for approximately 160 kilo tons in 2011. Demand for OSDF excipients was also highest from Europe accounting for over 30% of the total volume in 2011. However, the highest demand for Overall and OSDF excipients is expected from Asia Pacific due to the growth of the medical and food industry. In addition, increasing aging population in countries such as China and Japan are expected to contribute to the demand for excipients.


Some of the key participants profiled in the report include AkzoNobel, BASF, Cargill, Croda International Plc, Dow Chemical Company, Eastman Chemical Company, Evonik, Innophos Holdings Inc., The Lubrizol Corporation and Royal Dutch Shell Plc among others.
The report gives a comprehensive view of the excipients market in terms of volume and revenue. In addition, the report includes the demand forecast for each product type, based on volume and revenue. The report comprises the following segments:

Global Overall and OSDF Excipients Market: Product Segment Analysis

  • Polymers
  • Alcohols
  • Minerals
  • Gelatin
  • Sugar and Others

The report further segments the Overall and OSDF excipients product segments as:

Global Overall and OSDF Polymer Excipients Market: Product Segment Analysis

  • MCC
  • HPMC
  • Ethyl Cellulose
  • Methyl Cellulose
  • CMC
  • Croscarmellose Sodium
  • Povidone
  • Pregelatinized starch
  • Sodium starch glycolate
  • Polyethylene Glycol
  • Acrylic Polymers

Global Overall and OSDF Alcohol Excipients Market: Product Segment Analysis

  • Glycerin
  • Propylene Glycol
  • Sorbitol
  • Mannitol
  • Others

Global Overall and OSDF Alcohol Excipients Market: Product Segment Analysis

  • Calcium Phosphate
  • Calcium Carbonate
  • Clay
  • Silicon Dioxide
  • Titanium Dioxide
  • Others

Global Overall and OSDF Sugar and Other Excipients Market: Product Segment Analysis
  • Lactose
  • Sucrose
  • Others

The report provides a cross-sectional analysis of Overall and OSDF excipients with respect to the following regions:
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World


Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY – 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com

The generic drugs industry comprises of the manufacture and marketing of certain drugs which have the same active ingredients as the brand-name drugs manufactured by any pharmaceutical company. The major benefit of generic drugs is that the cost of such drugs is much less than that of branded drugs. Generic drugs come under the same governing framework as that of the brand-name drugs. The rationale behind generic drugs is that the patented drugs generally have a patent life of 20 years. However, the patent life of such drugs begins from the clinical trials and thus their commercial life is far less (approximately 15 years). After the patent expiry the manufacturers of such drugs face intense pricing pressure because of the competition from their cheap generic counterparts.


Sale of generic drugs also holds importance for entities such as wholesalers, pharmacies, and pharmacy benefit managers, as the sale of generic drugs provides higher profit margins than the sale of branded drugs. The generic drugs market is classified as simple generics, super-generics and biosimilars. Furthermore, the generic drugs market can be classified on the basis of their therapeutic applications such as anti-infective drugs, central nervous system drugs, cardiovascular products, anti-arthritis drugs, respiratory products, anti-cancer drugs and others. Geographically, North America is the largest consumer and manufacturer of generic drugs. In addition, the highest growth in this market is observed in Asia-Pacific. 

Some of the major generic drugs manufacturers include pharmaceutical companies such as Dr. Reddy’s Laboratories, Actavis, Mylan, Inc., Apotex, Inc., Ranbaxy Laboratories, Ltd, Hospira, Inc., Par Pharmaceutical, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries, Ltd., Watson Pharmaceuticals, Ltd. and others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  
This report provides comprehensive analysis of 
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 
All new upcoming reports: http://www.transparencymarketresearch.com/latest.php?type=U

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Reasons for Buying this Report:
  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth 
  • It provides a technological growth map over time to understand the industry growth rate
  • It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments